Levodopa and carbidopa — Competitive Intelligence Brief

Levodopa and carbidopa (Levodopa and carbidopa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor with peripheral decarboxylase inhibitor. Area: Neurology.

marketed Dopamine precursor with peripheral decarboxylase inhibitor Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa) Neurology Small molecule

Target snapshot

Levodopa and carbidopa (Levodopa and carbidopa) — NeuroDerm Ltd.. Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion of levodopa in the periphery, allowing more to reach the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levodopa and carbidopa TARGET	Levodopa and carbidopa	NeuroDerm Ltd.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa)
Sinemet (comparator)	Sinemet (comparator)	XenoPort, Inc.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (AADC); dopaminergic system
Levodopa Benserazide Madopar	Levodopa Benserazide Madopar	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide)
controlled-release levodopa / carbidopa	controlled-release levodopa / carbidopa	Pfizer	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
levodopa/dopa decarboxylase inhibitor	levodopa/dopa decarboxylase inhibitor	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (peripheral inhibition); dopamine receptors (central effect)
Levodopa + benserazide	Levodopa + benserazide	University of Buenos Aires	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition)
Levodopa / Carbidopa	Levodopa / Carbidopa	Ross D. Zafonte, MD	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor with peripheral decarboxylase inhibitor class)

1. Bial - Portela C S.A. · 2 drugs in this class
2. IRCCS San Raffaele Roma · 2 drugs in this class
3. NeuroDerm Ltd. · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Ross D. Zafonte, MD · 1 drug in this class
6. University of Buenos Aires · 1 drug in this class
7. AbbVie · 1 drug in this class
8. XenoPort, Inc. · 1 drug in this class
9. Intec Pharma Ltd. · 1 drug in this class